The Valeant Pipeline - Our Medicines in Development

Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Today, the company's pipeline combines both promising early and late-stage drug candidates that have unique formulations and mechanisms of action that addresses the need for new treatment regimens for epilepsy and new dermatology compounds for topical anti-fungals and rosacea. In addition, our efforts in ophthalmology are focused on therapeutic areas including glaucoma, dry eye, and retina. Valeant also plans to strategically expand its pipeline by adding new compounds and product extensions through company and product acquisitions.